CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Pegaptanib sodium

Last Updated: October 20, 2005
Result type: Reports
Project Number: SR0044-000
Product Line: Reimbursement Review

Generic Name: Pegaptanib sodium

Brand Name: Macugen

Manufacturer: Pfizer Canada Inc.

Therapeutic Area: Macular degeneration, age-related

Indications: Macular degeneration, age-related

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 25, 2006

Recommendation Type: Do not list